Analysis of the acute and chronic wound environments: the role of proteases and their inhibitors
- 1 November 1999
- journal article
- research article
- Published by Wiley in Wound Repair and Regeneration
- Vol. 7 (6) , 442-452
- https://doi.org/10.1046/j.1524-475x.1999.00442.x
Abstract
To assess the differences in proteolytic activity of acute and chronic wound environments, wound fluids were collected from acute surgical wounds (22 samples) and chronic wounds (25 samples) of various etiologies, including mixed vessel disease ulcers, decubiti and diabetic foot ulcers. Matrix metalloproteinase (MMP) activity measured using the Azocoll assay was significantly elevated by 30 fold in chronic wounds (median 22.8 μg MMP Eq/ml) compared to acute wounds (median 0.76 μg MMP Eq/ml) (p < 0.001). The addition of the matrix metalloproteinase inhibitor Illomostat decreased the matrix metalloproteinase activity by approximately 90% in all samples, confirming that the majority of the activity measured was due to matrix metalloproteinases. Gelatin zymograms indicated predominantly elevated matrix metalloproteinase‐9 with smaller elevations of matrix metalloproteinase‐2. In addition tissue inhibitor of metalloproteinase‐1 levels were analyzed in a small subset of acute and chronic wounds. When tissue inhibitor of metalloproteinase‐1 levels were compared to protease levels there was an inverse correlation (p = 0.02, r = – 0.78). In vitro degradation of epidermal growth factor was measured by addition of 125I labelled epidermal growth factor to acute and chronic wound fluid samples. There was significantly higher degradation of epidermal growth factor in chronic wound fluid samples (mean 28.1%) compared to acute samples (mean 0.6%). This also correlated to the epidermal growth factor activity of these wound fluid samples (p < 0.001, r = 0.64). Additionally, the levels of proteases were assayed in wound fluid collected from 15 venous leg ulcers during a nonhealing and healing phase using a unique model of chronic wound healing in humans. Patients with nonhealing venous leg ulcers were admitted to the hospital for bed rest and wound fluid samples were collected on admission (nonhealing phase) and after 2 weeks (healing phase) when the ulcers had begun to heal as evidenced by a reduction in size (median 12%). These data showed that the elevated levels of matrix metalloproteinase activity decreased significantly as healing occurs in chronic leg ulcers (p < 0.01). This parallels the processes observed in normally healing acute wounds. This data also supports the case for the addition of protease inhibitors in chronic wounds in conjunction with any treatments using growth factors.Keywords
This publication has 35 references indexed in Scilit:
- Wound Fluids from Human Pressure Ulcers Contain Elevated Matrix Metalloproteinase Levels and Activity Compared to Surgical Wound FluidsJournal of Investigative Dermatology, 1996
- Involvement of proteolytic enzymes—plasminogen activators and matrix metalloproteinases—in the pathophysiology of pressure ulcersWound Repair and Regeneration, 1995
- Metalloproteinase Activation Cascade After Burn Injury: A Longitudinal Analysis of the Human Wound EnvironmentJournal of Investigative Dermatology, 1994
- Collagenase in Wound Healing: Effect of Wound Age and TypeJournal of Investigative Dermatology, 1992
- The Safety and Effect of Topically Applied Recombinant Basic Fibroblast Growth Factor on the Healing of Chronic Pressure SoresAnnals of Surgery, 1992
- Recombinant Human Platelet-derived Growth Factor-BB for the Treatment of Chronic Pressure UlcersAnnals of Plastic Surgery, 1992
- Degradation of Fibronectin and Vitronectin and Vitronectin in Chronic Wound Fluid: Analysis by Cell Blotting, Immunoblotting, and Cell Adhesion AssaysJournal of Investigative Dermatology, 1992
- Human wound fluid from acute wounds stimulates fibroblast and endothelial cell growthPublished by Elsevier ,1991
- Tumor necrosis factor bifunctionally regulates matrix metalloproteinases and tissue inhibitor of metalloproteinases (TIMP) production by human fibroblastsFEBS Letters, 1990
- Enhancement of Wound Healing by Topical Treatment with Epidermal Growth FactorNew England Journal of Medicine, 1989